Funded Projects › FP7
ANGIOSCAFF · Angiogenesis-inducing Bioactive and Bioresponsive Scaffolds in Tissue Enginering
Angiogenesis underlies almost all biological processes of morphogenesis, including those in tissue repair and regeneration. Physiological angiogenesis is controlled by a complex interplay between cells and their environment: the extracellular matrix (ECM) provides signaling via numerous ECM adhesion molecules and growth factors bound to ECM polysaccharide components; and cells locally degrade and remodel the ECM to create pores into which angiogenic endothelial cells migrate. This observation, that physiological angiogenesis proceeds in response to solid-phase cues motivates our approach, namely creating bioactive resorbable materials as scaffolds that contain bound molecular signals to induce physiological angiogenesis in situations of tissue repair and regeneration. In some of our scaffold materials, porosity is inherent by virtue of fabrication, and in others porosity is created by cell-associated proteolysis as it is in physiological angiogenesis. All materials will be designed so as to be injectable or implantable into the human body. In some work, the final injectable/implantable material will comprise only materials and bioactive biomolecular signals, and in other cases it will also comprise cells. Thus, the concept of ANGIOSCAFF is to create materials that are bioresponsive (to environmental signals including pH and redox potential, and to cellular signals such as proteases), that are bioactive (by virtue of bound peptide or recombinant protein adhesion ligands and bound and releasable growth factors), and that are capable of carrying cellular therapeutics. To realize ANGIOSCAFF, we have assembled a team comprising both industrial and academic expert groups in biomaterials design and development, experts in the science and application of angiogenesis, in imaging in animal models, and in applications demanding biomaterials-based, angiogenesis-demanding tissue engineering therapies, including repair of bone, skin, cardiac muscle, skeletal muscle and nerve.
Consortium · 33 organisations
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE
CH · €2,267,214
KUROS BIOSURGERY AG
CH · €364,590
BIO-HYOS AB
SE · €353,519
NEWRON SWEDEN AB
SE · €87,600
BAYER INNOVATION GMBH
DE · €1,731
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
UK · €383,515
LUDWIG BOLTZMANN GESELLSCHAFT OSTERREICHISCHE VEREINIGUNG ZUR FORDERUNG DER WISSENSCHAFTLICHEN FORSCHUNG
AT · €514,866
BIORIGEN SRL
IT · €327,565
FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR
IT · €116,763
SMITH & NEPHEW UK LIMITED
UK · €8,089
MILTENYI BIOTEC GMBH
DE · €203,889
DANDO WEISS & COLUCCI LIMITED
UK · €338,566
FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA
ES · €407,465
UPPSALA UNIVERSITET
SE · €393,629
AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
ES · €345,124
University of Zurich
CH · €428,406
UNIVERSITAT ZU KOLN
DE · €462,364
FONDAZIONE MULTIMEDICA ONLUS
IT · €259,494
EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH
CH · €433,668
JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN
DE · €364,529
BAXALTA INNOVATIONS GMBH
AT · €34,800
IRCCS OSPEDALE POLICLINICO SAN MARTINO
IT
UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF
DE · €425,795
THE UNIVERSITY OF NOTTINGHAM
UK · €352,375
INTERCYTEX LTD
UK · €70,418
TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY
IL · €752,067
UNIVERSITY COLLEGE LONDON
€128,063
ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO
IT · €375,416
LEIBNIZ-INSTITUT FUR POLYMERFORSCHUNG DRESDEN EV
DE · €426,072
UNIVERSITATSSPITAL BASEL
CH · €350,036
UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA
IT · €224,985
IFOM-ISTITUTO FONDAZIONE DI ONCOLOGIA MOLECOLARE ETS
IT · €271,520
FONDAZIONE PARCO BIOMEDICO SAN RAFFAELE
IT · €157,108
Research fields
← Find collaborators and more funded projects
Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.